|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
NPV-BSK805, an Antineoplastic Jak2 Inhibitor Effective in Myeloproliferative Disorders, Causes Adiposity in Mice by Interfering With the Action of Leptin.
|
29867515 |
2018 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Although roles of somatic JAK2 mutations in clonally myeloproliferative neoplasms (MPNs) are well established, roles of germline JAK2 mutations in the pathogenesis of MPNs remain unclear.
|
29842959 |
2018 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
|
29767839 |
2018 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Somatic mutations in the calreticulin (CALR) gene have been found in most patients with JAK2- and MPL-unmutated Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs).
|
29741776 |
2018 |
|
Myeloproliferative disease
|
0.500 |
AlteredExpression
|
group |
BEFREE |
An inhibitor for the thrombopoietin receptor (TpoR) would be more specific for the treatment of myeloproliferative neoplasms (MPNs) due to constitutively active mutant TpoR compared to the current treatment approach of inhibiting Janus kinase 2 (JAK2).
|
29736709 |
2018 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The JAK2 V617F mutation is highly prevalent in patients with myeloproliferative neoplasms (MPN).
|
29717448 |
2018 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Renovascular hypertension associated with JAK2 V617F positive myeloproliferative neoplasms treated with angioplasty: 2 cases and literature review.
|
29656438 |
2018 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Ruxolitinib is a small molecule JAK-2 inhibitor approved for the treatment of certain myeloproliferative neoplasms.
|
29651917 |
2019 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
We also show that its expression is increased in both CD34<sup>+</sup> circulating progenitors and in the serum of patients with JAK2-dependent myeloproliferative neoplasms with fibrosis.
|
29650953 |
2018 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random?
|
29641446 |
2018 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
The roles of JAK2 in DNA damage and repair in the myeloproliferative neoplasms: Opportunities for targeted therapy.
|
29627078 |
2018 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Furthermore, the V617F mutation in JAK2 was identified in patients affected by myeloproliferative neoplasms.
|
29589523 |
2019 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Beyond JAK-2: potential targets for myeloproliferative neoplasm therapy.
|
29516749 |
2018 |
|
Myeloproliferative disease
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Ruxolitinib is a potent and selective JAK1/JAK2 inhibitor, with activity against myeloproliferative neoplasms (MPNs) including those harboring the JAK2V617F mutation.
|
29515770 |
2018 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.
|
29464483 |
2018 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In particular, gain-of-function mutations in the <i>JAK</i> genes, most frequently, V617F in the pseudokinase domain of JAK2, have been mapped in patients with blood disorders, including myeloproliferative neoplasms and leukemias.
|
29379470 |
2017 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.
|
29355841 |
2018 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Our data, reflecting the largest reported study comprehensively detailing clinicopathologic features and response to therapy, show that the co-occurrence of BCR-ABL1 and JAK2 V617F is rare, with an estimated frequency of 0.4%, and most often reflects two distinct ('composite') myeloproliferative neoplasms.
|
29327708 |
2018 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Philadelphia negative myeloproliferative neoplasms (MPNs) are characterized by frequent mutations of driver genes including JAK2, CALR and MPL.
|
29306106 |
2018 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Inhibition of the constitutively activated JAK/STAT pathway in JAK2V617F mutated cells by the JAK1/JAK2 inhibitor ruxolitinib resulted in clinical benefits in patients with myeloproliferative neoplasms.
|
29228564 |
2017 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
|
29214759 |
2018 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
V617F driver mutation of JAK2 is the leading cause of the Philadelphia-chromosome-negative myeloproliferative neoplasms (MPNs).
|
29202466 |
2018 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Detection of the JAK2 V617F mutation is a key step in the diagnosis of myeloproliferative neoplasms (MPN).
|
29150911 |
2018 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Negative valine (V) to phenylalanine (F) switch at the Janus kinase (JAK2) 617 codon (V617F) is the dominant driver mutation in patients with myeloproliferative neoplasms (MPNs).
|
29066347 |
2017 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) are classical myeloproliferative neoplasms (MPN), characterized by specific somatic mutations in JAK2, CALR or MPL genes.
|
29047144 |
2018 |